Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data.
Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data.
复制标题
使用基础胰岛素的不同2型糖尿病患者的血糖谱：移动的研究基线数据
DOI：
10.1111/dom.14238
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Price DA
中科院分区：
文献类型：
--
作者：
Peters A;Cohen N;Calhoun P;Ruedy KJ;Beck RW;Martens TW;Bao S;Njeru NM;Beck SE;Price DA
基础胰岛素通常用于控制不佳的2型糖尿病（T2 D）患者;然而，在许多情况下，其治疗效果不足。在移动的研究的基线阶段，我们评估了173名参与者的连续血糖监测（CGM）数据（平均值± SD，年龄57 ± 9岁; 50%女性; HbA 1c 9.1% [范围7.1%-11.6%]; 40%使用磺脲类药物; 19%使用NPH;报告自我监测血糖[SMBG]频率中位数1.0次检查/天）。在随机化前记录10天的盲态CGM数据。平均血糖值为208 ± 47 mg/dL，清晨最低。70 - 180 mg/dL范围内的平均时间为9.6 ± 6.1小时/天（40% ± 25%）。高血糖症广泛，中位数分别为14.7（61%）和5.0（20.9%）小时/天，血糖分别大于180和250 mg/dL。低血糖症不常见（中位[IQR] 0 [0，4. 3]分钟/天[0. 0%{0. 0%，0. 3%}]，血糖低于70 mg/dL）。设盲CGM突出了T2 D基础胰岛素使用者中SMBG不频繁的局限性，并允许在控制不佳的基础胰岛素使用者中表征高血糖和低血糖。移动的研究随机化阶段将确定在该人群中使用真实的CGM与SMBG相比的获益。
Basal insulin is often prescribed to patients with suboptimally controlled type 2 diabetes (T2D); however, its therapeutic efficacy is inadequate in many. During the MOBILE study's baseline phase, we evaluated 173 participants' continuous glucose monitoring (CGM) data (mean ± SD age 57 ± 9 years; 50% female; HbA1c 9.1% [range 7.1%‐11.6%]; 40% using sulphonylureas; 19% using NPH; reported self‐monitored blood glucose [SMBG] frequency median 1.0 checks/day) who were using basal, but not prandial insulin. Blinded CGM data were recorded for 10 days prior to randomization. The mean glucose value was 208 ± 47 mg/dL and it was lowest in the early morning. Mean time in the 70‐180 mg/dL range was 9.6 ± 6.1 hours/day (40% ± 25%). Hyperglycaemia was extensive with medians of 14.7 (61%) and 5.0 (20.9%) hours/day with glucose greater than 180 and 250 mg/dL, respectively. Hypoglycaemia was infrequent (median [IQR] 0 [0, 4.3] minutes/day [0.0% {0.0%, 0.3%}] with glucose less than 70 mg/dL). Blinded CGM highlights the limitations of infrequent SMBG in basal insulin users with T2D and allows characterization of hyperglycaemia and hypoglycaemia in basal insulin users with suboptimal control. The MOBILE study randomized phase will define the benefits of using real‐time CGM compared with SMBG in this population.
登录
查看更多内容
影响因子：
2.9
作者：
Kalirai, Samaneh;Stephenson, Judith;Fisher, Lawrence
通讯作者：
Fisher, Lawrence
影响因子：
5.8
作者：
Karl, D. M.;Gill, J.;Riddle, M. C.
通讯作者：
Riddle, M. C.
影响因子：
16.2
作者：
Vigersky, Robert A.;Fonda, Stephanie J.;Ehrhardt, Nicole M.
通讯作者：
Ehrhardt, Nicole M.
影响因子：
5.8
作者：
Li, Pengxiang;Geng, Zhi;Doshi, Jalpa A.
通讯作者：
Doshi, Jalpa A.
影响因子：
16.2
作者：
Battelino, Tadej;Danne, Thomas;Phillip, Moshe
通讯作者：
Phillip, Moshe